Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.
Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.
The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.